CVKD Key Statistics, Chart & Performance
The current stock price of CVKD is 9.92 USD. In the past month the price decreased by -22.98%. In the past year, price decreased by -34.69%.
CVKD Latest News, Press Relases and Analysis
CVKD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.47 | 1.05T | ||
| JNJ | JOHNSON & JOHNSON | 19.91 | 497.73B | ||
| MRK | MERCK & CO. INC. | 11.99 | 263.92B | ||
| PFE | PFIZER INC | 8.04 | 146.23B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.48 | 99.84B | ||
| ZTS | ZOETIS INC | 20.17 | 56.68B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 23.06B | ||
| VTRS | VIATRIS INC | 4.53 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.41 | 11.64B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.23 | 8.44B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.50B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.46B |
Related stock screener links
About CVKD
Company Profile
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 4 full-time employees. The company went IPO on 2023-01-20. The Company’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Tecarfarin has orphan drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including left ventricular assisted devices (LVADs). The firm also has ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). The company also includes Frunexian, a Phase 2-ready IV Factor XIa agent for acute anticoagulation and EP-7327 is a ready oral small molecule candidate for chronic indications.
Company Info
CADRENAL THERAPEUTICS INC
822 A1a North, Suite 306
Ponte Vedra FLORIDA US
Employees: 4
Phone: 19043000701
CADRENAL THERAPEUTICS INC / CVKD FAQ
What does CADRENAL THERAPEUTICS INC do?
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 4 full-time employees. The company went IPO on 2023-01-20. The Company’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Tecarfarin has orphan drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including left ventricular assisted devices (LVADs). The firm also has ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). The company also includes Frunexian, a Phase 2-ready IV Factor XIa agent for acute anticoagulation and EP-7327 is a ready oral small molecule candidate for chronic indications.
What is the current price of CVKD stock?
The current stock price of CVKD is 9.92 USD. The price decreased by -1.2% in the last trading session.
What is the dividend status of CADRENAL THERAPEUTICS INC?
CVKD does not pay a dividend.
What is the ChartMill technical and fundamental rating of CVKD stock?
CVKD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting CVKD stock to perform?
8 analysts have analysed CVKD and the average price target is 36.38 USD. This implies a price increase of 266.73% is expected in the next year compared to the current price of 9.92.
What is the GICS sector and industry of CVKD stock?
CADRENAL THERAPEUTICS INC (CVKD) operates in the Health Care sector and the Pharmaceuticals industry.
What is CADRENAL THERAPEUTICS INC worth?
CADRENAL THERAPEUTICS INC (CVKD) has a market capitalization of 20.63M USD. This makes CVKD a Nano Cap stock.
CVKD Technical Analysis
CVKD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CVKD. While CVKD seems to be doing ok healthwise, there are quite some concerns on its profitability.
CVKD Financial Highlights
Over the last trailing twelve months CVKD reported a non-GAAP Earnings per Share(EPS) of -8.01. The EPS decreased by -19.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -351.94% | ||
| ROE | -525.99% | ||
| Debt/Equity | 0 |
CVKD Forecast & Estimates
8 analysts have analysed CVKD and the average price target is 36.38 USD. This implies a price increase of 266.73% is expected in the next year compared to the current price of 9.92.